Workday, Inc. , the AI platform for managing people, money, and agents, plans to announce its fiscal 2026 first quarter financial results after market close on Thursday, May 22, 2025. The company will ...

Calabrio, the workforce performance company, has appointed Frank Ciccone as Chief Revenue Officer (CRO), effective immediately. Ciccone will lead Calabrio's global Sales, Partners and Alliances, and ...

IO Biotech was named to Fast Company’s World’s Most Innovative Companies of 2025 list for its potentially game-changing approach to immune-modulatory cancer vaccines, earning its place on the coveted ...

IO Biotech Stock Up 1.0% NASDAQ IOBT opened at $1.00 on Monday. The firm’s 50-day simple moving average is $0.95 and its two-hundred day simple moving average is $0.94.

NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines ...

NEW YORK - IO Biotech (IOBT), a clinical-stage biopharmaceutical firm with a market capitalization of approximately $61 million, has presented new preclinical data on two therapeutic cancer ...

IO Biotech's co-founder presented advancements in cancer vaccines at the 2025 AACR Annual Meeting, highlighting innovative therapeutic strategies. IO Biotech, a clinical-stage biopharmaceutical ...

(Abstract #2241) IO170, also developed using IO Biotech’s T-win® platform, demonstrated significant tumor growth inhibition in breast and prostate cancer mouse models. The TGF- β-directed ...

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines ...

Preclinical data further support the potential of dual-antigen and TGF-β-directed vaccines to reshape the tumor microenvironment and drive anti-tumor immunity NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) ...

IO Biotech presents preclinical data supporting dual-antigen and TGF-β-targeted vaccines for enhancing anti-tumor immunity at AACR 2025. IO Biotech presented new preclinical data at the AACR ...